Gulf Pharmaceutical Industries
JULPHAR.AEOverview
Julphar's mission is to provide a better quality of life by delivering best-in-class, accessible pharmaceutical solutions. The company has achieved a position as one of the largest generic drug producers in the MEA region, with a commercial footprint spanning over 50 countries and state-of-the-art manufacturing facilities. Its strategy is centered on expanding its portfolio of complex generics and biosimilars, supported by strategic partnerships and a focus on operational excellence to drive revenue growth and margin expansion.
Technology Platform
Advanced pharmaceutical manufacturing and formulation platform for complex generics and biosimilars, encompassing cell line development, bioprocessing, and analytical characterization to ensure quality and cost-effectiveness.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Julphar Insulin R (soluble human insulin, biosimilar) + Humi... | Diabetes Mellitus | Phase 1 | |
| Julphar Insulin N (human isophane insulin) + Huminsulin® Bas... | Diabetes Mellitus | Phase 1 | |
| human biphasic insulin + human biphasic insulin, reference | Diabetes Mellitus | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Julphar is a regional leader competing with local generic firms and MNC subsidiaries. In biosimilars, it will face global giants; its strategy relies on regional expertise, cost advantages, and partnerships to secure a niche.